Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Indication, Route of Administration, Country, and Region - Analysis and Forecast, 2025-2035

June 2026 | - | ID: AC672DDB1A62EN
BIS Research Inc.

Abstracts

Alpha-1 Antitrypsin Deficiency is a rare, inherited metabolic disorder caused by mutations in the SERPINA1 gene, leading to deficient or dysfunctional alpha-1 antitrypsin protein. This protein plays a crucial role in protecting lung tissue from enzymatic damage. The deficiency primarily manifests as pulmonary emphysema and hepatic dysfunction, depending on protein misfolding and accumulation patterns.

The market is driven by rising R&D investments in protein augmentation and gene replacement therapies, increasing awareness and diagnosis of rare respiratory disorders, and strong orphan drug designations supporting innovation. Current treatment approaches focus on augmentation therapy (IV infusions of purified AAT protein), inhaled formulations for respiratory protection, and emerging gene-editing therapies aiming to provide long-term correction. Ongoing clinical trials targeting molecular restoration, protein folding enhancement, and RNA-based correction strategies underscore the growing technology landscape.

Market Lifecycle Stage

The global Alpha-1 Antitrypsin Deficiency market is currently positioned in the growth stage, characterized by the coexistence of established augmentation therapies and an accelerating pipeline of gene and RNA-based treatments. While augmentation therapy remains the primary standard for pulmonary Alpha-1 Antitrypsin Deficiency, next-generation gene therapies and RNA interference platforms are advancing through mid to late-stage clinical development, offering the potential for long-term correction and functional cure. Market expansion is further supported by increased awareness, early diagnostic initiatives, and orphan drug incentives promoting investment in rare disease research. Nevertheless, high treatment costs, complex administration protocols, and limited patient accessibility continue to pose challenges. Despite these constraints, the evolving therapeutic landscape presents substantial opportunities for innovation and commercialization through 2035.

Market Segmentation:

Segmentation 1 - By Indication

• Pulmonary Alpha-1 Antitrypsin Deficiency
• Hepatic Alpha-1 Antitrypsin Deficiency
• Others

Pulmonary Alpha-1 Antitrypsin Deficiency dominates the market due to its higher prevalence and established augmentation therapy base. Treatments focus on intravenous alpha-1 protein infusions and investigational inhaled formulations that improve pulmonary function and reduce exacerbations. Hepatic Alpha-1 Antitrypsin Deficiency represents a growing research area, with emerging therapies addressing protein misfolding and hepatocellular damage. Other indications, including systemic or paediatric forms, are being explored in early-stage trials, supported by advances in molecular therapy and clinical research collaborations.

Segmentation 2 - By Route of Administration

• Intravenous
• Inhaled
• Others

Intravenous administration remains the leading route, primarily for augmentation therapy, offering systemic protein restoration and well-documented clinical efficacy. However, inhaled delivery is gaining momentum due to its potential for localized pulmonary targeting, improved convenience, and enhanced patient compliance. Other routes, including subcutaneous or gene-based vector administration, are under investigation, focusing on sustained efficacy, reduced dosing frequency, and improved quality of life for patients with chronic Alpha-1 Antitrypsin Deficiency.

Segmentation 3 - By Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

North America leads the global Alpha-1 Antitrypsin Deficiency market, supported by robust reimbursement structures, high disease awareness, and established augmentation therapy infrastructure. Europe follows closely, driven by clinical collaborations, orphan drug policies, and strong government support for rare diseases. The Asia-Pacific region is emerging rapidly due to increased screening efforts, healthcare infrastructure expansion, and growing investment in biologic and gene-based therapy research. The Rest of the World, including Latin America, the Middle East, and Africa, shows gradual market penetration, with efforts focused on improving diagnosis rates and therapy access through international partnerships.

Demand – Drivers and Limitations

Demand drivers for the global Alpha-1 Antitrypsin Deficiency market:

• Rising R&D investment in gene and protein replacement therapies improving efficacy and safety profiles
• Increasing diagnosis and awareness of rare respiratory and hepatic disorders supporting therapy adoption
• Expansion of orphan drug designations and government-backed incentives encouraging innovation and faster regulatory approvals

Limitations for the global Alpha-1 Antitrypsin Deficiency market:

• High cost and limited accessibility of augmentation therapy, especially in low-resource regions
• Lack of curative treatments and complex trial designs limiting widespread adoption and development efficiency

How can this report add value to an organisation?

Product/Innovation: The report provides an in-depth evaluation of existing and emerging therapies, including augmentation, inhaled, and gene therapies. It enables R&D teams to identify unmet clinical needs, promising molecular targets, and partnership opportunities. Mapping innovation hotspots and clinical progress helps prioritize research investments and supports the design of next-generation, disease-modifying therapeutic solutions.

Growth/Marketing: Through insights on regional treatment trends, patient demographics, and therapy adoption, the report assists organizations in crafting targeted market-entry and expansion strategies. Understanding reimbursement frameworks, regulatory incentives, and competitive therapy landscapes helps align commercialization plans with regions showing the highest growth potential and clinical demand for Alpha-1 Antitrypsin Deficiency treatments.

Competitive: Comprehensive benchmarking of leading pharmaceutical companies, active pipelines, and collaborative ventures provides stakeholders with strategic intelligence for decision-making. The report enables competitive positioning, co-development opportunity identification, and differentiation strategies within the evolving rare respiratory and hepatic disorder market landscape.

Key Market Players and Competitive Landscape

This report provides a comprehensive competitive analysis of pharmaceutical companies developing and commercializing treatment solutions for Alpha-1 Antitrypsin Deficiency. Evaluation parameters include clinical-stage assets, marketed therapies, strategic alliances, and R&D investments. Key players include:

• Arrowhead Pharmaceuticals
• Grifols, S.A.
• Kamada Pharmaceuticals
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Vertex Pharmaceuticals Incorporated
• Wave Life Sciences USA, Inc.

The market is characterized by expanding R&D pipelines in gene therapy, protein replacement, and inhaled delivery approaches designed to address both pulmonary and hepatic manifestations of Alpha-1 Antitrypsin Deficiency.

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary
Scope of Study
Definition
Inclusion and Exclusion Criteria

1. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY MARKET: INDUSTRY OUTLOOK

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
  1.2.1 U.S.
  1.2.2 EU
    1.2.2.1 Germany
    1.2.2.2 France
  1.2.3 Rest-of-the-World
1.3 Market Trends
1.4 Clinical Trial Analysis
1.5 Regulatory Landscape Analysis
  1.5.1 Legal Requirement and Framework in U.S.
  1.5.2 Legal Requirement and Framework in E.U.
  1.5.3 Legal Requirement and Framework in Asia-Pacific
  1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.6 Market Dynamics
  1.6.1 Impact Analysis
  1.6.2 Market Drivers
  1.6.3 Market Restraints
  1.6.4 Market Opportunities

2. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY MARKET, BY INDICATION, $MILLION, 2024-2035

2.1 Pulmonary AATD
2.2 Hepatic AATD
2.3 Others

3. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION, $MILLION, 2024-2035

3.1 Intravenous
3.2 Inhaled
3.3 Others

4. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY MARKET, BY REGION, $MILLION, 2024-2035

4.1 North America
  4.1.1 Key Findings
  4.1.2 Market Dynamics
  4.1.3 Market Sizing and Forecast
    4.1.3.1 North America Alpha-1 Antitrypsin Deficiency Market (by Country)
      4.1.3.1.1 U.S.
      4.1.3.1.2 Canada
4.2 Europe
  4.2.1 Key Findings
  4.2.2 Market Dynamics
  4.2.3 Market Sizing and Forecast
    4.2.3.1 Europe Alpha-1 Antitrypsin Deficiency Market (by Country)
      4.2.3.1.1 Germany
      4.2.3.1.2 France
      4.2.3.1.3 Italy
      4.2.3.1.4 Spain
      4.2.3.1.5 U.K.
      4.2.3.1.6 Rest-of-Europe
4.3 Asia-Pacific
  4.3.1 Key Findings
  4.3.2 Market Dynamics
  4.3.3 Market Sizing and Forecast
    4.3.3.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Market (by Country)
      4.3.3.1.1 Japan
      4.3.3.1.2 Rest-of-Asia-Pacific
4.4 Rest-of-the-World
  4.4.1 Key Findings
  4.4.2 Market Dynamics
  4.4.3 Market Sizing and Forecast

5. GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY MARKET: COMPETITIVE BENCHMARKING AND COMPANY PROFILES

5.1 Competitive Benchmarking
5.2 Competitive Landscape
  5.2.1 Key Strategies and Developments by Company
    5.2.1.1 Funding Activities
    5.2.1.2 Mergers and Acquisitions
    5.2.1.3 Regulatory Approvals
    5.2.1.4 Partnerships, Collaborations, and Business Expansions
  5.2.2 Key Developments Analysis
5.3 Company Profiles
  5.3.1 Arrowhead Pharmaceuticals
    5.3.1.1 Company Overview
    5.3.1.2 Product Portfolio
    5.3.1.3 Target Customers/End Users
    5.3.1.4 Key Personnel
    5.3.1.5 Analyst View
  5.3.2 Grifols, S.A.
    5.3.2.1 Company Overview
    5.3.2.2 Product Portfolio
    5.3.2.3 Target Customers / End Users
    5.3.2.4 Key Personnel
    5.3.2.5 Analyst View
  5.3.3 Kamada Pharmaceuticals
    5.3.3.1 Company Overview
    5.3.3.2 Product Portfolio
    5.3.3.3 Target Customers / End Users
    5.3.3.4 Key Personnel
    5.3.3.5 Analyst View
  5.3.4 Sanofi S.A.
    5.3.4.1 Company Overview
    5.3.4.2 Product Portfolio
    5.3.4.3 Target Customers / End Users
    5.3.4.4 Key Personnel
    5.3.4.5 Analyst View
  5.3.5 Takeda Pharmaceutical Company Limited
    5.3.5.1 Company Overview
    5.3.5.2 Product Portfolio
    5.3.5.3 Target Customers / End Users
    5.3.5.4 Key Personnel
    5.3.5.5 Analyst View
  5.3.6 Vertex Pharmaceuticals Incorporated
    5.3.6.1 Company Overview
    5.3.6.2 Product Portfolio
    5.3.6.3 Target Customers / End Users
    5.3.6.4 Key Personnel
    5.3.6.5 Analyst View
  5.3.7 Wave Life Sciences USA, Inc.
    5.3.7.1 Company Overview
    5.3.7.2 Product Portfolio
    5.3.7.3 Target Customers / End Users
    5.3.7.4 Key Personnel
    5.3.7.5 Analyst View
  5.3.8 Others

6. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Alpha-1 Antitrypsin Deficiency Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Alpha-1 Antitrypsin Deficiency Market, 2024 and 2035
Figure: Global Alpha-1 Antitrypsin Deficiency Market Key Trends, Impact Analysis, 2024-2035
Figure: North America Alpha-1 Antitrypsin Deficiency Market, $Million, 2024-2035
Figure: Europe Alpha-1 Antitrypsin Deficiency Market, $Million, 2024-2035
Figure: Asia-Pacific Alpha-1 Antitrypsin Deficiency Market, $Million, 2024-2035
Figure: Rest-of-the-World Alpha-1 Antitrypsin Deficiency Market, $Million, 2024-2035

List Of Tables

LIST OF TABLES

Table: Market Snapshot
Table: Market Dynamics
Table: Global Alpha-1 Antitrypsin Deficiency Market (by Indication), $Million, 2024-2035
Table: Global Alpha-1 Antitrypsin Deficiency Market (by Route of Administration), $Million, 2024-2035
Table: Global Alpha-1 Antitrypsin Deficiency Market (by Region), $Million, 2024-2035